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INTRODUCTION
Health systems deliver preventive, diagnostic, cura-
tive and palliative health care services to people in order 
to improve their health. Health systems in the Euro-
pean Union (EU) Member States are varied, reflecting 
different societal choices. Over the last decade, Euro-
pean health systems have faced consistent, common 
challenges: increasing cost of health care, population 
ageing associated with a rise of chronic diseases and 
multi-morbidity leading to growing demand for health 
care, shortages and uneven distribution of health pro-
fessionals, health inequalities and inequities in access 
to health care. Moreover, in recent years, the economic 
crisis has limited the financial resources available and 
thus aggravated Member States’ difficulties in ensuring 
their health systems’ sustainability. In turn, this jeop-
ardises Member States’ ability to provide universal ac-
cess to good quality health care. Health systems need 
to be resilient: they must be able to adapt effectively to 
changing environments, tackling significant challenges 
with limited resources [1].
This is particularly true for rare diseases [2, 3]. These 
conditions are a threat to the health of EU citizens in-
sofar as they are life-threatening or chronically debili-
tating disorders with a low prevalence and a high level 
of complexity. Rare diseases are defined as conditions 
affecting no more than 5 per 10 000 persons in the EU. 
Despite their rarity, there are so many different types of 
rare diseases that millions of people are affected. It is 
estimated that between 5000 and 8000 distinct rare dis-
eases exist today, affecting between 6% and 8% of the 
population in the course of their lives. In other words, 
the total number of people affected by rare diseases in 
the EU is between 27 and 36 million. Most of them 
suffer from less frequently occurring diseases affecting 
one in 100 000 people or less. These patients are par-
ticularly isolated and vulnerable [4].
Distribution of public spending on health depends 
on a variety of factors, from disease burden and sys-
tem priorities to organisational aspects and costs [5, 6]. 
Nowadays, virtually all health care systems face serious 
sustainability challenges. In the case of rare disease, pri-
ority setting involves complex value-laden choices that 
are often ethically controversial. This controversy arises, 
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in part, because it involves conflicting moral obligations 
– beneficence versus distributive justice – which results 
in different levels of funding and opposing interests of a 
number of involved stakeholders [7]. Nevertheless, EU 
health policy is built on principles and overarching val-
ues of universality, access to good quality care, equity 
and solidarity. These are of paramount importance for 
patients with rare diseases. Because of their low prev-
alence, their specificity and the high total number of 
people affected, rare diseases call for a global approach 
based on special and combined efforts to prevent sig-
nificant morbidity or avoidable premature mortality, 
and to improve the quality of life and socioeconomic 
potential of affected persons [2-4, 8].
METHOD
The theoretical framework underlying the approach 
of this work is based upon the State of Health in the 
EU, a two-year initiative undertaken by the Europe-
an Commission that provides policy makers, interest 
groups and health practitioners with factual, compara-
tive data and insights into health and health systems in 
EU countries [9, 10]. The cycle is developed in coop-
eration with the Organisation for Economic Co-opera-
tion and Development and the European Observatory 
on Health Systems and Policies. It is also aligned to the 
policy objectives set out in the 2014 Commission Com-
munication on effective, accessible and resilient health 
systems [1].
RESULTS
The 2017 State of Health in the EU report provides 
an in-depth analysis of EU Member States’ health sys-
tems. It looks at the health of the population and im-
portant risk factors, as well as at the effectiveness, ac-
cessibility and resilience of health systems in each EU 
member state. 
Five cross-cutting conclusions come forward [10].
Health promotion and disease prevention pave  
the way for a more effective and efficient health 
system
Prevention is the key to avoid ill health and achieve a 
high level of mental and physical well-being effectively 
and efficiently. However, only a small fraction of health 
care budgets, political attention and stakeholder en-
gagement are dedicated to prevention. Guided by the 
UN Sustainable Development Goal for 2030 to reduce 
by one third premature mortality from non-communi-
cable diseases, the Commission is working closely with 
Member States to focus on prevention and social deter-
minants of health [10].
A strong primary care guides patients through  
the health system and helps avoid wasteful spending
Strong primary care can contribute to strengthening 
the overall health system’s performance by providing 
affordable and accessible care, coordinating care for 
patients so that they are given the most appropriate 
services in the right setting, and reducing avoidable 
hospital admissions. Efficient primary care is the key to 
integration and continuity between and across levels of 
care, which is essential for patients, particularly those 
with complex needs [10].
Integrated care tackles a labyrinth of scattered health 
services to the benefit of the patient
The rising burden of chronic disease and multi-mor-
bidity requires countries to confront the fragmentation 
of health services and shift towards integration: linking 
or coordinating providers along the continuum of care 
and putting the patient at the centre. Integrated care 
models are expected to contribute for better effective-
ness, accessibility and resilience of health systems. This 
new challenge demonstrates also the importance of the 
right skill mix and training and of being able to share 
information effectively [10].
Proactive health workforce planning and forecasting 
make health systems resilient to future shocks
To strengthen prevention, primary care and inte-
grated service delivery, health systems need a workforce 
of sufficient capacity and with the right skills and flex-
ibility to meet the changing demands of health care. 
Yet many countries are confronted with critical health 
workforce problems such as supply, distribution and a 
traditionally oriented skill mix. Reforms in initial educa-
tion and training programmes and investment in con-
tinuous professional development are needed to foster 
new and appropriate skill sets [10].
The patient is at the centre of the next generation  
of better health data for policy and practice
More holistic, person-centred health data would have 
an enormous potential for improving the quality of 
care and the performance of health systems across the 
EU. Data capturing patient experiences and outcomes 
could markedly enrich knowledge on all topics. Genera-
tion of better information will provide a set of tools to 
more effectively treat patients with increasingly com-
plex conditions and multiple morbidities, and deliver 
the outcomes that patients value the most [10].
IMPLICATIONS AND RECOMMENDATIONS
The 2017 State of Health in the EU report concludes 
that only by rethinking health systems it can be ensured 
that they remain fit-for-purpose and provide patient-
centred care [10]. Sustainability and resilience of health 
systems for rare diseases could be achieved by tackling 
the challenges identified and making the right health 
policy choices [2, 3]. Rare diseases have been one of the 
priorities of the Community’s programmes for research 
and development [4]. In order to improve the coordina-
tion and coherence of national, regional and local initia-
tives addressing rare diseases, the EU has stimulated a 
series of actions in the field of rare diseases. These proj-
ect activities could set up in fact the practical coopera-
tion and come up with the knowledge to translate and to 
work on the identified five key challenges of EU Mem-
ber States health systems’ sustainability and resilience.
Switching the focus to prevention and the social 
determinants of health
Health promotion and disease prevention pave the 
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way for a more effective and efficient health system. 
Aside from the unbalanced investments in prevention, 
social inequalities need to be tackled [10]. In this con-
text, the EUROCAT Project provided essential epide-
miologic information on congenital anomalies in Eu-
rope. The project evaluated the effectiveness of primary 
prevention and assessed the impact of developments in 
prenatal screening. The outcomes of the project activ-
ity could act as an information and resource centre for 
the population, health professionals and managers re-
garding clusters or exposures or risk factors of concern, 
as well as could provide a ready collaborative network 
and infrastructure for research related to the causes and 
prevention of congenital anomalies and the treatment 
and care of affected children [11-14]. The BURQOL-
RD Project has addressed the social determinants of 
health in rare diseases in Europe. The project gener-
ated a methodological framework to measure the socio-
economic burden of and health-related quality of life 
in rare diseases. It performed a pilot study and its out-
comes could help refining and packing tools for con-
tinuous and extensive focus on the social impact of rare 
diseases [15-17].
Guiding patients through the health system with 
strong primary care
Strong primary care efficiently guides patients 
through the health system and helps avoid wasteful 
spending [10]. In the context of rare diseases, newborn 
screening is a cost-effective approach that results in 
improvements in expectancy and quality of life for af-
fected infants. This is of paramount importance in the 
primary care for rare diseases, as it could eliminate the 
need for an otherwise expensive diagnostic odyssey, by 
substantially decreasing extra referrals and psychologi-
cal stress for patients and caregivers [18]. In 2009, the 
Commission launched a tender on evaluation of popu-
lation newborn screening practices for rare disorders in 
the Member States. This project activity reported on 
the practices of neonatal screening for rare disorders 
in all Member States, estimated the number of infants 
screened and the number of disorders included in the 
newborn screening and described the reasons for the se-
lection of these disorders. It successfully identified types 
of medical management and follow-up implemented in 
the Member States and established a network of ex-
perts analysing the information and formulating a final 
opinion containing recommendations on best practices 
and recommending a core panel of newborn screening 
conditions. These outcomes could help Member States 
in medical management and follow-up of rare disease 
patients, fostering primary care and avoiding unneces-
sary referrals [19-21].
Integrating care for a sustainable and effective 
service
Integrated care ensures that a patient receives joined-
up care. It avoids the situation, where care is frag-
mented and patients have to search their way through a 
maze of care facilities. Health systems in the European 
Union aim to provide high-quality, cost-effective care 
[10]. This is particularly difficult however, in cases of 
low-prevalence and complex rare disease. In this con-
text, the EU established 24 European reference net-
works in 2017 that involve more than 900 highly-spe-
cialised healthcare units from over 300 hospitals in 26 
Member States. These networks are working on a range 
of thematic issues, including bone disorders, childhood 
cancer and immunodeficiency. The European Refer-
ence Networks are virtual networks aiming to facilitate 
discussion on complex or rare diseases and conditions 
that require highly specialised treatment and concen-
trated knowledge and resources. In the context of sus-
tainability and resilience of health systems, European 
reference networks could help applying EU criteria to 
tackle rare diseases requiring specialised care, as well 
as ensuring the availability of treatment facilities where 
necessary [22-24].
Creating a health workforce resilient to future 
challenges
Proactive health workforce planning and forecast-
ing make health systems resilient to future evolutions. 
Health authorities need to prepare their workforce for 
upcoming changes: an ageing population and multi-
morbidity, the need for sound recruitment policies, new 
skills and technical innovation [10]. In the context of 
rare diseases, promotion and communication on the 
management of rare diseases by disseminating trust-
worthy guidelines globally is a key issue. The RARE-
Bestpractices Project created a platform to improve the 
management of rare disease patients. The project built 
a comprehensive public database of trustworthy guide-
lines, ranging from diagnostic tests and treatments to 
the organisation of care, to help professionals, patients, 
policy makers with the best and most up to date infor-
mation. It also produced mechanisms to identify and 
prioritise rare disease clinical research needs in order 
to optimise, as well as to redefine the clinical research 
agenda taking into consideration both patients’ and cli-
nicians’ interests. These outcomes are very important 
and could help setting up training activities targeted at 
key stakeholders to spread expertise and knowledge in 
the field of guidelines [25-27]. Orphanet, the portal for 
rare diseases and orphan drugs, could also greatly con-
tribute for achieving these goals [28-30].
Addressing an important knowledge gap with better, 
patient-centred data
Patients should be at the centre of the next genera-
tion of better health data for policy and practice. The 
digital transformation of health and care helps cap-
ture real-world outcomes and experiences that matter 
to patients, with great potential for strengthening the 
effectiveness of health systems [10]. In this context, 
support for registries and databases for rare diseases is 
crucial. The EPIRARE Project defined the state of the 
art of existing registries with reference to their legal ba-
sis, organisational and IT measures used, type of data 
collected, compliance with the rules on personal data 
protection, quality assurance, operational and finan-
cial support. The project agreed on a minimum data 
set for all rare diseases and defined criteria for quality 
assessment of data, data sources and procedures in the 
HealtH systems for rare diseases
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registries. These outcomes could help determining the 
scope, operation and governance model of rare disease 
registry platforms, balancing the interests of relevant 
stakeholders and ensuring long-term sustainability [31-
33].
Further observations in relation to the sustainabil-
ity of health systems for rare diseases relate to the 
availability of resources for health systems: while so-
cial and demographic pressures increase demand for 
health care, and technological and scientific advances 
continue to increase costs, in Europe, the financial 
crisis posed major threats to healthcare sustainability. 
Governments’ response to the crisis was cutting public 
health-care budgets, and transferring healthcare costs 
to individuals and families through out-of-pocket pay-
ments. As a result, not only equity was jeopardized, 
suffering the least wealthy from the greatest health 
effects, but also austerity policies affected economic 
growth much more adversely than previously believed. 
Moreover, while little research has been done about the 
health consequences of the crisis, groups concerned 
with biomedicine, pharmaceuticals, and medical tech-
nologies are driving the process for setting health re-
search priorities, and government ministries of science 
have coordinated them nationally with little input from 
Ministries of Health. Considering the complexity of 
policy-making and the process of resource allocation 
for healthcare, the WHO identified whole-of-govern-
ment and whole-of-society approaches as a set of tools 
to manage the complex policy process and identified 
the following features for comparing good governance 
practices [34]:
• Forward looking: long-term view based on statistical 
trends and informed predictions of the probable im-
pact of the policy;
• Innovative: questioning established methods and en-
couraging new ideas;
• Informed by evidence: using the best available evi-
dence from a range of sources;
• Inclusive: taking account of the impact of the policy 
on the needs of everyone directly or indirectly af-
fected;
• Joined-up: horizontal and vertical integration;
• Adaptive: learning from experience of what works 
and what does not;
• Evaluative: including systematic evaluation;
• Accountable: being democratically legitimized, trans-
parent and responsive to the demands of citizens.
According to Aluttis and coll. [35], organizational 
structure, resources, partnership, workforce, knowledge 
development, leadership and governance and country 
specific play a relevant role in public health. The same 
factors are crucial for health systems sustainability 
for rare diseases as well. The organizational structure 
shapes the infrastructural ability of the system to con-
tribute to the goals to healthcare systems for rare dis-
eases. Allocation and provision of human and financial 
resources to healthcare systems for rare diseases; col-
laboration among organizations for effective practice; 
qualified human resources with adequate skills and 
knowledge; all of them are fundamental for healthcare. 
Knowledge development is the base providing informa-
tion on the health status and supporting evidence-based 
health policy and interventions at all levels; leadership 
and governance represent the ability and willingness of 
governments to improve public health, since they de-
velop and implement effective health policies and ex-
pressing qualities in strategic thinking. Therefore, all of 
them represent key elements and mechanisms for the 
sustainability of the health systems for rare diseases.
In relation to the financial sustainability, government 
have the responsibility of allocating resources to the dif-
ferent public sectors. Following the financial crisis that 
hit Europe, budgets for healthcare decreased, inequali-
ties in health increased. According to the International 
organization Oxfam, several countries have success-
fully reduced economic inequality by means of cracking 
down on financial secrecy and tax dodging; redistribu-
tive transfers; and strengthening of social protection 
schemes; investment in universal access to healthcare 
and education; progressive taxation; strengthening 
wage floors and worker rights [36].
Oxfam calls on governments to use their tax revenue 
to provide universal healthcare, education and social 
protection for citizens. Moreover, it has recommended 
policies in multiple contexts to strengthen the political 
representation of citizens to achieve greater equity, un-
derlining the importance of citizens’ active participation 
in the mechanisms of resilience. These policies include:
- a global goal to end extreme economic inequality in 
every country. This should be a major element of the 
post-2015 framework, including consistent monitoring 
in every country of the share of wealth going to the rich-
est one percent;
- stronger regulation of markets to promote sustain-
able and equitable growth; and
- curbing the power of the rich to influence political 
processes and policies that best suit their interests.
In order to address fiscal pressure in future, internation-
al and national policy-makers should aim to:
- develop better information systems, in order to get 
timely and relevant data to monitor health effects of 
economic shock;
- strengthen health financing policy design: public 
spending on health is more explicitly linked to popula-
tion health needs; the public revenue base is not overly 
reliant on employment; and tax subsidies do not foster 
inequalities in paying for and accessing health services; 
- invest in measures to promote efficiency; 
- foster governance and leadership at international and 
national levels.
CONCLUSIONS
We used the five identified axes of public health chal-
lenges in the 2017 State of Health in the EU report 
to start a broad debate on the issue of sustainability 
of health care systems for rare diseases. Our analysis 
is suggesting a number of possible ways by which the 
outcomes of successful EU-funded projects could help 
addressing and achieving sustainability and resilience of 
health systems for rare diseases.
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